Saudi Pharmaceutical Appliances (2070) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Saudi Pharmaceutical Appliances SAR 26.19, price SAR 32.50, upside -19.4%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Saudi Pharmaceutical Appliances for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 21.16 SAR – 58.61 SAR · fair‑value band 18.18 SAR – 34.29 SAR · the 32.50 SAR price screens above the 26.19 SAR fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Saudi Pharmaceutical Appliances in your weekly email
Every Wednesday you see whether Saudi Pharmaceutical Appliances is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia, the Middle East, Egypt, Algeria, and Morocco. The company operates through Pharmaceutical Manufacturing, Trading and Distribution Services, and Healthcare Services segments.
Show more
Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia, the Middle East, Egypt, Algeria, and Morocco. The company operates through Pharmaceutical Manufacturing, Trading and Distribution Services, and Healthcare Services segments. The company is involved in the sale, marketing, and distribution of pharmaceutical, veterinary, medical equipment, and cosmetics products; and operates and maintains a secondary care hospital. In addition, it manufactures human medicines, and wholesales and retails of medicines and related products. Further, the company engages in the research and development of medical science activities, and investment business in related industries. The company was incorporated in 1986 and is headquartered in Buraydah, the Kingdom of Saudi Arabia.
Stock analysis
Saudi Pharmaceutical Appliances (2070) currently trades at 32.50 SAR, while our model-based Fair Value estimate is 26.19 SAR, implying the stock looks roughly 24.1% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 26.83 SAR per share, and 4 of the 24 models we run sit above the 32.50 SAR price.
Bear case: the Asset-Based group reads lowest at 8.96 SAR, and 20 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 18.18 SAR (bear) to 34.29 SAR (bull), the price of 32.50 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Saudi Pharmaceutical Appliances reported revenue of 1.7B SAR in FY2025 versus 1.5B SAR in FY2021, a compound +4.0%/yr. Reported net income was 184M SAR in FY2025, compounding +62.5%/yr from FY2021.
Key figures
Market cap 3.9B SAR (≈ $1.0B) · P/E ratio 21.7 · P/S ratio 2.34 · EPS (TTM) 1.50 SAR · Dividend yield 1.1% · Net margin 10.8% · Return on equity 11.0% · Return on assets (EBIT) 1.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −19%, 2070 screens richer than that median.
Fair Value models
Bear 18.18 SARFair Value 26.19 SARBull 34.29 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.8444 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Start year 2020 (pandemic). Over 10 years: +0.0% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+20.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.6%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.20% vs −6%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 16%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (Saudi Arabia: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +15.8% a year for the price and +3.4% for the forecasts.
Compare Saudi Pharmaceutical Appliances with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−20% · Below median
Profitability
Return on equity (TTM)11% · Above median
Return on assets4% · Above median
Net margin (TTM)11% · Above median
Operating margin (TTM)21% · Top 25%
Growth and dividend
Revenue growth−13% · Bottom 25%
Dividend yield (TTM)1.1% · Below median
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Saudi Pharmaceutical Appliances (2070) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 26.19 SAR versus a price of 32.50 SAR, about −19% upside (overvalued).
What is the fair value of 2070?
Our model-based fair value for Saudi Pharmaceutical Appliances is 26.19 SAR (as of Sep 24, 2026), built from audited fundamentals. The current price: 32.50 SAR.
What is the quality score of 2070?
Saudi Pharmaceutical Appliances has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Saudi Pharmaceutical Appliances (2070)?
Our model-based price target is the fair value of 26.19 SAR (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 18.18 SAR, optimistic scenario 34.29 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Saudi Pharmaceutical Appliances stock forecast for 2026?
Our models put fair value at 26.19 SAR, about −19% upside versus a price of 32.50 SAR (overvalued). Cautious scenario 18.18 SAR, optimistic scenario 34.29 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Saudi Pharmaceutical Appliances (2070)?
Saudi Pharmaceutical Appliances reported trailing-twelve-month revenue of about 1.6B SAR (latest available figure, as of Sep 24, 2026).
Does Saudi Pharmaceutical Appliances pay a dividend?
Saudi Pharmaceutical Appliances currently shows a dividend yield of about 1.08% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Saudi Pharmaceutical Appliances (2070)?
For today's price to be fair in a discounted-cash-flow model, Saudi Pharmaceutical Appliances would have to grow free cash flow by +18.2 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 2070 use?
Our models discount Saudi Pharmaceutical Appliances at 10.3 %: a base by market capitalisation (small), damped by beta 0.41, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Saudi Pharmaceutical Appliances that is +18.2 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Saudi Pharmaceutical Appliances (2070) delivered so far?
Over the past 5 years revenue at Saudi Pharmaceutical Appliances grew +1.8 % a year. The price currently implies +18.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Saudi Pharmaceutical Appliances (2070) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Saudi Pharmaceutical Appliances (+18.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Saudi Pharmaceutical Appliances (2070)?
The free-cash-flow yield on the price is 4.44 %: that much free cash flow Saudi Pharmaceutical Appliances produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Saudi Pharmaceutical Appliances (2070)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Saudi Pharmaceutical Appliances it is 26.19 SAR per share (as of Sep 24, 2026), against a price of 32.50 SAR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Saudi Pharmaceutical Appliances stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 2070 trades above its calculated fair value: price 32.50 SAR, fair value 26.19 SAR, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2070?
No. The price is what the market pays today (32.50 SAR); the fair value is what the company's own numbers justify (26.19 SAR). For Saudi Pharmaceutical Appliances the two are 6.31 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Saudi Pharmaceutical Appliances worth?
The market values Saudi Pharmaceutical Appliances at about 3.9B SAR (market capitalisation, as of Sep 24, 2026). Per share that is 32.50 SAR; our models calculate a fair value of 26.19 SAR per share.
What do the bullish and bearish scenarios say about 2070?
Our models span a range for Saudi Pharmaceutical Appliances: cautious scenario 18.18 SAR, base 26.19 SAR, optimistic 34.29 SAR per share (as of Sep 24, 2026, price 32.50 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2070?
Saudi Pharmaceutical Appliances trades at a price-to-earnings ratio of 21.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 26.19 SAR is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 19.0 (reported for FY2025: 16.4). Other multiples: P/B 0.7, P/S 0.6, EV/EBITDA 4.0.
How solid is the balance sheet of Saudi Pharmaceutical Appliances (2070)?
Balance-sheet figures for Saudi Pharmaceutical Appliances (as of Sep 24, 2026): return on equity 11.0%, debt of 0.29 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 2070 from its 52-week high?
Saudi Pharmaceutical Appliances trades at 32.50 SAR, about 1% below its 52-week high of 32.94 SAR and 31% above the low of 24.75 SAR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 26.19 SAR is for.
Which stocks are comparable to Saudi Pharmaceutical Appliances?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Saudi Pharmaceutical Appliances stock attractive at the current price?
The data as of Sep 24, 2026: price 32.50 SAR, calculated fair value 26.19 SAR (−19%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2070 calculated?
We run Saudi Pharmaceutical Appliances through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 26.19 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Saudi Pharmaceutical Appliances itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Saudi Pharmaceutical Appliances (2070)?
The closing price on Sep 24, 2026 was 32.50 SAR. Our model-based fair value is 26.19 SAR, about −19% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Saudi Pharmaceutical Appliances right now?
Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (18.18 SAR to 34.29 SAR) leaves room in how you read the outcome.
Key figures of Saudi Pharmaceutical Appliances
How large is the market capitalisation of Saudi Pharmaceutical Appliances (2070)?
The market capitalisation of Saudi Pharmaceutical Appliances is 3.9B SAR (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Saudi Pharmaceutical Appliances (2070)?
The price-to-sales ratio of Saudi Pharmaceutical Appliances is 2.34 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Saudi Pharmaceutical Appliances (2070)?
Earnings per share at Saudi Pharmaceutical Appliances are 1.50 SAR (price ÷ EPS = P/E 21.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Saudi Pharmaceutical Appliances (2070)?
The dividend yield of Saudi Pharmaceutical Appliances is 1.1% (payout 23.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Saudi Pharmaceutical Appliances (2070)?
The net margin of Saudi Pharmaceutical Appliances is 10.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Saudi Pharmaceutical Appliances (2070)?
The return on equity (ROE) of Saudi Pharmaceutical Appliances is 11.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Saudi Pharmaceutical Appliances (2070)?
On an EBIT basis the return on assets of Saudi Pharmaceutical Appliances is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Saudi Pharmaceutical Appliances (2070)?
The operating margin of Saudi Pharmaceutical Appliances is 21.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Saudi Pharmaceutical Appliances (2070)?
Revenue at Saudi Pharmaceutical Appliances is growing −12.6% versus a year earlier (3y avg +6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Saudi Pharmaceutical Appliances (2070)?
Earnings per share at Saudi Pharmaceutical Appliances are growing −8.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Saudi Pharmaceutical Appliances (2070) carry?
The net debt of Saudi Pharmaceutical Appliances is 1.2B SAR (fiscal year 2025, ≈ 7.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Saudi Pharmaceutical Appliances in the live analysis
One click puts Saudi Pharmaceutical Appliances on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
